Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Find the latest information on COVID-19, monkeypox, and the flu vaccine

Does a psychiatric history play a role in the development of psychiatric adverse events to perampanel… and to placebo? Epilepsy & behavior : E&B Kanner, A. M., Patten, A., Ettinger, A. B., Helmstaedter, C., Meador, K. J., Malhotra, M. 2021; 125: 108380

Abstract

The purpose of this study was to establish whether a past psychiatric history could play a role in the development of psychiatric treatment-emergent adverse events (PTEAEs) in patients randomized to perampanel (PER) or placebo.The development of PTEAEs was compared between patients with/without a psychiatric history in a post hoc analysis from four randomized placebo-controlled trials (RPCTs) of PER (304/305/306/335) in patients with treatment-resistant focal epilepsy.Among the 2,187 patients enrolled in the RPCTs, 352 (16.1%) had a psychiatric history (PER n?=?244; placebo n?=?108), while 1835 patients (83.9%) did not (PER n?=?1325; placebo n?=?510). Compared to patients without a psychiatric history, those with a positive history reported more PTEAEs for both patients randomized to PER (11.8% vs. 29.9%, p?

View details for DOI 10.1016/j.yebeh.2021.108380

View details for PubMedID 34735963